Get the Stockscreener App
72.89
0.75%
-0.55
After Hours:
72.23
-0.66
-0.91%
Moderna Inc stock is traded at $72.89, with a volume of 3.37M.
It is down -0.75% in the last 24 hours and down -11.43% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$73.44
Open:
$73.44
24h Volume:
3.37M
Relative Volume:
0.91
Market Cap:
$28.02B
Revenue:
$4.99B
Net Income/Loss:
$-5.87B
P/E Ratio:
-7.7957
EPS:
-9.35
Net Cash Flow:
$-3.98B
1W Performance:
-5.83%
1M Performance:
-11.43%
6M Performance:
-25.70%
1Y Performance:
-32.66%
1-Day Range:
$71.65
$73.60
1-Week Range:
$71.51
$77.75
52-Week Range:
$62.55
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? - Benzinga
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit - Morningstar
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - Markets Insider
Is It Time to Buy August's Worst-Performing Nasdaq Stocks? - The Motley Fool
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows - Benzinga
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - MSN
Pandemic darling Moderna needs a reality check | Company Business News - Mint
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - Yahoo Finance
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - Zacks Investment Research
Pandemic Darling Moderna Needs a Reality Check - The Wall Street Journal
MRNA LAWSUIT ALERT: Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Moderna's updated COVID vaccine nears EU approval - Investing.com
Moderna mpox mRNA vaccine shows early promise in monkey study - Pharmaceutical Technology
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. - GlobeNewswire
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before - The Bakersfield Californian
Moderna mpox mRNA vaccine shows early promise in monkey study - Clinical Trials Arena
Moderna mpox mRNA vaccine shows early promise in monkey study - Yahoo Finance
Bavarian Nordic stock slides on Moderna mpox vaccine study (NASDAQ:MRNA) - Seeking Alpha
Moderna: CHMP gives green light to new Covid vaccine - Marketscreener.com
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again? - The Motley Fool
Moderna updated COVID shot endorsed in EU (NASDAQ:MRNA) - Seeking Alpha
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 - Yahoo Finance
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your RightsMRNA - PR Newswire
Column: Some people can wait to get the new COVID shot - Yakima Herald-Republic
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 - Via Ritzau
Moderna, Inc. ShareholdersRobbins LLP Reminds MRNA - GlobeNewswire
Some people can wait to get the new COVID shot - 코리아타임스
UK, Taiwan Approve Moderna's Updated COVID-19 Shot - MSN
Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock - MarketBeat
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - Stockhouse Publishing
Mpox Protection: Moderna’s New mRNA Vaccine May Beat Today’s MVA Shot - Genetic Engineering & Biotechnology News
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
Moderna's mRNA-based mpox vaccine shows promise in trials - UPI News
Moderna MRNA Mpox Vaccine Shows Promise In Animal Study - Barron's
Moderna’s experimental mpox vaccine reduces severity of disease, study finds - MarketWatch
COVID shots are no longer free for the uninsured - WWNY
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 - GlobeNewswire
Moderna Receives MHRA Authorisation for Updated Covid-19 Vaccine - European Pharmaceutical Manufacturer
MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Moderna’s COVID-19 mRNA vaccine targeting SARS-COV-2 Variant JN.1 receives approval in Taiwan - BSA bureau
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRNA - PR Newswire
What's Going On With Moderna Stock On Tuesday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna: green light for new Covid vaccine in the UK - Marketscreener.com
Moderna, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring - Barron's
Moderna’s updated COVID-19 vaccine wins U.K. approval (NASDAQ:MRNA) - Seeking Alpha
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):